Global Novel Oral Anticoagulants (NOAC) Market Size To Exceed USD 31.97 Billion By 2035 | CAGR Of 8.68%
Category: HealthcareGlobal Novel Oral Anticoagulants (NOAC) Market Size To Exceed USD 31.97 Billion By 2035
According to a research report published by Spherical Insights & Consulting, The Global Novel Oral Anticoagulants (NOAC) Market Size is Expected To Grow from USD 12.80 Billion in 2024 to USD 31.97 Billion by 2035, at a CAGR of 8.68% during the forecast period 2025-2035.
Get more details on this report -
Browse key industry insights spread across 201 pages with 119 Market data tables and figures & charts from the report on the " Global Novel Oral Anticoagulants (NOAC) Market Size, Share, and COVID-19 Impact Analysis, By Drug Type (Dabigatran, Rivaroxaban, Apixaban, Edoxaban, and Others), By Application (Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035. "Get Detailed Report Description Here:https://www.sphericalinsights.com/reports/novel-oral-anticoagulants-noac-market
Novel oral anticoagulants (NOAC) Market Size are a more recent class of oral anticoagulant drugs that are not vitamin K antagonists. The extended therapeutic indications, safety monitoring, and patient selection are becoming more and more important in the regulatory criteria for NOACs. As long as dose modification and renal function factors are taken into account, organizations such as the FDA, EMA, and international associations now advise NOACs over conventional VKAs in non-valvular atrial fibrillation, particularly in older and fragile patients. Because NOACs such as apixaban, edoxaban, dabigatran, and rivaroxaban are more cost effective than warfarin, they are commonly recommended for stroke prevention in Health Technology Assessments in a number of nations. NOACs can lower the incidence of venous thromboembolism recurrence in cancer patients more than low molecular weight heparin, according to meta-analyses and randomized trials e.g., Hokusai VTE Cancer, SELECT-D, Caravaggio, although they should be used with caution while treating gastrointestinal cancers. NOACs are also being validated in orthopedics a meta-analysis of patients who had complete hip and knee replacements reveals that NOACs lower the risk of VTE compared to non NOAC therapy without significantly increasing the risk of serious bleeding. However, the Novel Oral Anticoagulants (NOAC)'s high treatment cost and bleeding risk & safety concerns are likely going to restrict market expansion.
The dabigatran segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.
Based on the drug type, The Novel Oral Anticoagulants (NOAC) Market Size is divided into dabigatran, rivaroxaban, apixaban, edoxaban, and others. Among these, the dabigatran segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The segment's development is stimulated by its early entry into the market for direct thrombin inhibitors, its good clinical trial data for preventing stroke in patients with atrial fibrillation and VTE, its availability of reversal medications such as idarucizumab, and its low number of food and drug interactions. Its rise is anticipated to be further driven by the rising incidence of AF, the aging population, and generic entrants.
The atrial fibrillation segment accounted for the largest share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.
Based on the application, the novel oral anticoagulants (NOAC) market is divided into atrial fibrillation, deep vein thrombosis, pulmonary embolism, and others. Among these, the atrial fibrillation segment accounted for the largest share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. The segment's increase is prompted by the need for diagnostic, pharmacological, and interventional treatments, which are growing as atrial fibrillation is becoming more common, particularly in older populations, and has a significant risk of consequences, including stroke.
Get more details on this report -
North America is expected to hold the majority share of the global novel oral anticoagulants (NOAC) market during the forecast period.
North America is expected to hold the majority share of the global novel oral anticoagulants (NOAC) market during the forecast period. The novel oral anticoagulants (NOAC) market is encouraged by the fact of its high rate of cardiovascular diseases, sophisticated healthcare system, robust regulatory frameworks, early adoption of clinical recommendations that support NOACs, and substantial public and private healthcare expenditures.
Get more details on this report -
Asia Pacific is anticipated to grow at the fastest pace in the global novel oral anticoagulants (NOAC) market during the forecast period. The novel oral anticoagulants (NOAC) market in the Asia Pacific is bolstered by the growing prevalence of cardiovascular disorders, the population's rapid aging, the expansion of insurance coverage and healthcare access, the greater inclusion of NOACs in national reimbursement lists, the growing knowledge of patients and doctors, and the availability of more reasonably priced generic equivalents.
Europe is a key driver of the global novel oral anticoagulants (NOAC) market due to a number of significant factors. The region's advanced healthcare system and well-established reimbursement practices enable the widespread usage of NOACs. Countries with strong clinical guidelines and high physician compliance, such as Germany, the UK, and France, are the most likely to prescribe NOACs. The aging of the population and the increased prevalence of cardiovascular diseases are contributing factors to the growing need for effective anticoagulant therapies.
Major vendors in the global novel oral anticoagulants (NOAC) market are Johnson & Johnson, Boehringer Ingelheim, Sanofi, Daiichi Sankyo, Armatheon, Aspen, AstraZeneca, Bayer, Cellceutix, Cosmo Pharmaceuticals, CSL Behring, Eisai, GSK, Marathon Pharmaceuticals, Ockham Biotech, and Others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Recent Development
In December 2020, Natco Pharma announced the launch of its Rivaroxaban product under the brand RPIGAT in India. It’s available in four strengths (20 mg, 15 mg, 10 mg, 2.5 mg). The move is part of Natco’s strategy to offer more affordable NOACs in the Indian market.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the novel oral anticoagulants (NOAC) market based on the following segments:
Global Novel Oral Anticoagulants (NOAC) Market, By Drug Type
- Dabigatran
- Rivaroxaban
- Apixaban
- Edoxaban
- Others
Global Novel Oral Anticoagulants (NOAC) Market, By Application
- Atrial Fibrillation
- Deep Vein Thrombosis
- Pulmonary Embolism
- Others
Global Novel Oral Anticoagulants (NOAC) Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?